Looking to expand your partner network with leading companies like AXON Neuroscience? Consider joining Inpart's global network for free.
News and Trends 2 Sep 2021
AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II results this week, raising tentative hopes for the field of treatments targeting the protein tau. For decades, the major culprit responsible for Alzheimer’s disease was suggested to be the buildup of a protein called amyloid-beta in the brain. Blocking this […]
